Lombard Medical: Aorfix stent shows positive results in all patients

By Lisa Kerner

Charlotte, N.C., Sept. 11 - Lombard Medical Technologies plc said data from its Aorfix stent graft study in Poland showed that all 18 patients were free from abdominal aortic aneurysm-related mortality, aneurysm rupture, stent migration, stent fracture and device-related endoleaks after 24 months.

In addition, the study showed a measured decrease in aneurysm diameter 83% of the cases.

"In terms of freedom from device-related endoleak, the results are superior to those reported by competitor products in the more simple anatomies," chairman Alistair Taylor said in a news release.

"Furthermore the level of device migration is comparable to the market leader and superior to all other products."

The positive clinical data was presented at the Cardiovascular and Interventional Radiological Society of Europe meeting in Rome.

Lombard is a medical devices company based in Didcot and Sheffield, United Kingdom.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.